Recent discussions on X about Vaxart, Inc. (VXRT) have centered around the company’s announcement of a proxy statement for a reverse stock split, aimed at supporting the resumption of trading on Nasdaq. Many users are debating the potential impact of this move on the stock’s future, with some expressing cautious optimism about the company’s strategic direction. This development has sparked renewed interest in Vaxart’s position within the biotech sector.
Additionally, there’s been notable chatter about Vaxart’s progress with an oral tablet vaccine candidate for norovirus, highlighted in a recent scientific article shared on the platform. Posts on X reflect curiosity about how this could position the company in the competitive vaccine market, especially given the unique delivery method. The conversation continues to evolve as investors weigh the long-term implications of these updates.
Note: This discussion summary was generated from an AI condensation of post data.
Vaxart, Inc. Insider Trading Activity
Vaxart, Inc. insiders have traded $VXRT stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $VXRT stock by insiders over the last 6 months:
- STEVEN LO (President, Chief Exec Officer) purchased 100,000 shares for an estimated $49,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Vaxart, Inc. Hedge Fund Activity
We have seen 26 institutional investors add shares of Vaxart, Inc. stock to their portfolio, and 35 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIO CAPITAL MANAGEMENT, LLC removed 5,931,867 shares (-51.5%) from their portfolio in Q1 2025, for an estimated $2,414,269
- MILLENNIUM MANAGEMENT LLC removed 2,034,776 shares (-68.0%) from their portfolio in Q1 2025, for an estimated $828,153
- CITADEL ADVISORS LLC removed 501,623 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $204,160
- JONES FINANCIAL COMPANIES LLLP added 478,111 shares (+276364.7%) to their portfolio in Q1 2025, for an estimated $194,591
- SILVERARC CAPITAL MANAGEMENT, LLC removed 393,957 shares (-36.6%) from their portfolio in Q1 2025, for an estimated $160,340
- VANGUARD GROUP INC added 291,506 shares (+2.9%) to their portfolio in Q1 2025, for an estimated $118,642
- SQUAREPOINT OPS LLC added 287,677 shares (+55.7%) to their portfolio in Q1 2025, for an estimated $117,084
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Vaxart, Inc. Analyst Ratings
Wall Street analysts have issued reports on $VXRT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B. Riley Securities issued a "Buy" rating on 03/27/2025
To track analyst ratings and price targets for Vaxart, Inc., check out Quiver Quantitative's $VXRT forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
